Tools
Stock profile

Axogen, Inc. (AXGN)

AXGN · Latest close $56.95 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$56.95
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
3
vs previous quarter

Axogen, Inc. (AXGN) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $173.9K sold). Latest close $56.95 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 2, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-173.9K
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RTW Investments · Perceptive Advisors · Disciplined Growth Investors — 5 tracked funds hold AXGN. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($173.9K). Insider trading

Often held alongside

EXAGEN INC. (XGN) · PLEXUS CORP (PLXS) · RadNet, Inc. (RDNT) · GENERAC HOLDINGS INC. (GNRC) · INTUITIVE SURGICAL INC (ISRG) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RTW Investments0.40%1,011,576NEW Q3 filed Nov 16
Perceptive Advisors0.17%247,312TRIMMED (-64.5%) Q3 filed Nov 16
Disciplined Growth Investors0.10%127,859TRIMMED (-35.0%) Q3 filed Nov 16
First Eagle Investment Management0.03%341,077TRIMMED (-3.8%) Q3 filed Nov 10
Mairs & Power Funds0.01%22,000HELD Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +25.8% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

58.637.322024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding253 of 8,857 filers
Long-only filers among them252
Change vs 2026 Q1+39 net · 246 entered · 207 exited
Shares reported, all filers52,582,302
Reported value, all filers$2.3B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryElectromedical & Electrotherapeutic Apparatus (SIC 3845)
Revenue · FY2025$225.2M
Net income · FY2025$-15.7M
Total assets · FY2025$221.7M
Shares outstanding59,730,715
Market cap (at latest close)$3.4B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 26, 2026.

Short interest

Shares short · Oct 15, 20265,123,544
Share of shares outstanding8.58%
Days to cover3.02

Shares short at recent settlements — Jul 31, 2026: 4.1M · Aug 14, 2026: 3.4M · Aug 31, 2026: 3.8M · Sep 15, 2026: 4.1M · Sep 30, 2026: 4.7M · Oct 15, 2026: 5.1M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 26, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 9K · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 26, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($173.9K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 2, 2026TYNDALL JOSEPH A.Sell3,500$49.70$173.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 2, 2026JOSEPH A TYNDALLDirector3,500$174.6KSep 2, 2026SEC filing
Aug 11, 2026AMY MCBRIDE-WENDELLDirector13,353$643.9KAug 11, 2026SEC filing
Aug 10, 2026MARC BEGANOfficer67,500$3.1MAug 10, 2026SEC filing
Aug 7, 2026KATHY WEILERDirector14,150$627.6KAug 7, 2026SEC filing
May 8, 2026AMY MCBRIDE-WENDELLDirector1,647$70.2KMay 8, 2026SEC filing
May 7, 2026JOHN H JOHNSONDirector11,050$478.0KMay 7, 2026SEC filing
May 7, 2026DORIS QUACKENBUSHVice President of Sales3,878$168.7KMay 7, 2026SEC filing
May 7, 2026JENS KEMPOfficer4,000$173.8KMay 7, 2026SEC filing
May 7, 2026KATHY WEILERDirector16,344$720.6KMay 7, 2026SEC filing
Dec 16, 2025Amy McBride-WendellDirector43,684$1.3MDec 16, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Oct 2, 2026Divisadero Street Capital Management, LPSC 13G3,983,7836.8%Oct 2, 2026SEC filing
Aug 14, 2026First Light Asset Management, LLCSC 13G/A3,746,3807.0%Jun 30, 2026SEC filing
Jul 31, 2026Vanguard Capital ManagementSC 13G/A2,654,4455.0%Jun 30, 2026SEC filing
May 7, 2026First Light Asset Management, LLCSC 13G/A3,291,4636.2%Apr 30, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G2,659,7765.1%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Nov 14, 2025First Light Asset Management, LLCSC 13G/A5,647,28212.2%Sep 30, 2025SEC filing
May 15, 2025ArrowMark Colorado Holdings, LLCSC 13G/A1,591,1033.6%Mar 31, 2025SEC filing
May 2, 2025Soleus Capital Master Fund, L.P.SC 13G/A1,446,1173.7%Mar 31, 2025SEC filing
Feb 3, 2025Morgan StanleySC 13G/A2,330,4065.3%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 30 Lobbying Disclosure Act filings named this company as client, 2010–2026; most common issues: Health Issues (24), Medical/Disease Research/Clinical Labs (4), Veterans (1).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Growth — Latest revenue: $225.2M · 5-yr revenue CAGR: 14.9% · Straight growth years: 15

· Gross Profitability (Novy-Marx) — Gross profit / assets: 75.5% · Gross margin: 74.3%

· Distress Risk (Altman Z″) — Z″-Score: -0.43 · Working capital / assets: 0.44 · Retained earnings / assets: -1.38 · EBIT / assets: -0.04 · Equity / liabilities: 1.39

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q3, ranked #26 of 50.

Also held by the tracked funds that hold AXGN — ranked by lift, the co-holding pattern described in Methodology: EXAGEN INC. (XGN) · PLEXUS CORP (PLXS) · RadNet, Inc. (RDNT) · GENERAC HOLDINGS INC. (GNRC) · INTUITIVE SURGICAL INC (ISRG).

Recent 8-K filings

FiledItemsSource
Nov 9, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 28, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 1, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

EXAGEN INC. (XGN) · Track Record: how the signals scored · Practice timing on AXGN

One email a week: the week’s new filings and research. Subscribe free

← AX  ·  AXIAY →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.